VBI Vaccines Inc. (NASDAQ: VBIV) stock fell -3.87% on Friday to $0.73 against a previous-day closing price of $0.76. With 1.32 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.57 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7800 whereas the lowest price it dropped to was $0.7150. The 52-week range on VBIV shows that it touched its highest point at $3.49 and its lowest point at $0.64 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 1.85.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VBIV was down-trending over the past week, with a drop of -10.96%, but this was down by -27.46% over a month. Three-month performance dropped to -23.91% while six-month performance fell -54.49%. The stock lost -78.00% in the past year, while it has lost -68.69% so far this year. A look at the trailing 12-month EPS for VBIV yields -0.39 with Next year EPS estimates of -0.26. For the next quarter, that number is -0.08. This implies an EPS growth rate of -29.20% for this year and 29.70% for next year.
Float and Shares Shorts:
At present, 258.26 million VBIV shares are outstanding with a float of 204.57 million shares on hand for trading. On Jul 14, 2022, short shares totaled 16.51 million, which was 6.39% higher than short shares on Jun 14, 2022. In addition to Mr. Jeffery R. Baxter F.C.M.A., FCMA as the firm’s Pres, CEO & Director, Mr. Christopher McNulty serves as its CFO, Head of Bus. Devel. & Director.
Through their ownership of 50.68% of VBIV’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.69% of VBIV, in contrast to 34.74% held by mutual funds. Shares owned by individuals account for 26.24%. As the largest shareholder in VBIV with 20.27% of the stake, Perceptive Advisors LLC holds 52,334,993 shares worth 52,334,993. A second-largest stockholder of VBIV, BlackRock Fund Advisors, holds 12,534,427 shares, controlling over 4.85% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in VBIV, holding 12,372,113 shares or 4.79% stake. With a 1.59% stake in VBIV, the iShares Russell 2000 ETF is the largest stakeholder. A total of 4,095,541 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.34% of VBIV stock, is the second-largest Mutual Fund holder. It holds 3,463,874 shares valued at 3.1 million. iShares Russell 2000 Value ETF holds 0.75% of the stake in VBIV, owning 1,925,801 shares worth 1.73 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VBIV since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VBIV analysts setting a high price target of $7.00 and a low target of $5.00, the average target price over the next 12 months is $6.00. Based on these targets, VBIV could surge 858.9% to reach the target high and rise by 584.93% to reach the target low. Reaching the average price target will result in a growth of 721.92% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VBIV will report FY 2022 earnings on 02/27/2023. Analysts have provided yearly estimates in a range of -$0.29 being high and -$0.42 being low. For VBIV, this leads to a yearly average estimate of -$0.37. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. VBI Vaccines Inc. surprised analysts by -$0.02 when it reported -$0.09 EPS against a consensus estimate of -$0.07. Based on analyst estimates, the high estimate for the next quarter is -$0.08 and the low estimate is -$0.08. The average estimate for the next quarter is thus -$0.08.
Summary of Insider Activity:
Insiders traded VBIV stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 5 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 24,600 while 2,707,463 shares were sold.